Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Patent
1998-01-20
2000-10-17
Bansal, Geetha P.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
4241851, 4241781, 4241301, 514 2, 514834, 530827, 530829, 530381, 530407, A61K 3900, A61K 39395, A61K 3800, C07K 1400, C07K 3514
Patent
active
061327298
ABSTRACT:
The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.
REFERENCES:
patent: 4536387 (1985-08-01), Sakamoto et al.
patent: 5017556 (1991-05-01), O'Brien et al.
patent: 5110730 (1992-05-01), Edgington et al.
patent: 5223427 (1993-06-01), Edgington
patent: 5314695 (1994-05-01), Brown
patent: 5346991 (1994-09-01), Roy et al.
patent: 5374617 (1994-12-01), Morrissey et al.
patent: 5437864 (1995-08-01), Edgington et al.
patent: 5504064 (1996-04-01), Morrissey et al.
patent: 5504067 (1996-04-01), Morrissey et al.
patent: 5589173 (1996-12-01), O'Brien et al.
patent: 5589363 (1996-12-01), Roy et al.
patent: 5622931 (1997-04-01), Edgington et al.
patent: 5726147 (1998-03-01), Ruf et al.
patent: 5739101 (1998-04-01), Roy et al.
Co-Pending U.S. Application No. 09/009,822, filed Jan. 20, 1998; (Attorney Docket No. UTSD:517).
Co-Pending U.S. Application No. 09/009,656, filed Jan. 20, 1998; (Attorney Docket No. UTSD:537).
International Search Report Dated Jul. 31, 1998 (PCT/US98/01012)(UTFD:517P--).
Thorpe et al., "Tumor infarction: immunoconjugates that coagulate the vasculature of solid tumor," Eighty-Sixth Annual Meeting of the American Association for Cancer Research, Toronto, Ontario, Canada, Mar. 18-22, Abstract No. 2910, Proc. Amer. Assoc. Cancer Res. 36:448, 1995.
Burrows and Thorpe, "Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature," Proc. Natl. Acad. Sci. USA 90:8996-9000, 1993.
Burrows et al., "A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors," Cancer Res. 52:5954-5962, 1992.
Denekamp, "Vascular attack as a therapeutic strategy for cancer," Cancer Metastasis Rev. 9:267-282, 1990.
Dvorak et al., "Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies," Cancer Cells. 3:77-85, 1991.
Edgington et al., "The structural biology of expression and function of tissue factor," Thromb. Haemost. 66(1):67-79, 1991.
Fisher et al., "Cloning and expression of human tissue factor cDNA," Thromb. Res. 48:89-99, 1987.
Hagemeier et al., "A monoclonal antibody reacting with endothelial cells of budding vessels in tumors and inflammatory tissues, and non-reactive with normal adult tissues," Int. J. Cancer 38:481-488, 1986.
Huang et al., "Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature," Science 275:547-550, 1997.
Martin, "Tissue factor: molecular recognition and cofactor function," FASEB J. 9:852-859, 1995.
Morrissey et al., "Molecular cloning of the cDNA for tissue factor, the cellular receptor for initiation of the coagulation protease cascade," Cell 50:129-135, 1987.
Murray et al., "Tumor-derived factors which induce endothelial tissue factor and enhance the procoagulant response to TNF," Int. J. Radiat. Biol. 60:273-277, 1991.
Nawroth et al., "Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas," J. Exp. Med. 168:637-648, 1988.
Nemerson, "Tissue factor and hemostasis," Blood 71(1):1-8, 1988.
Neuenschwander and Morrissey, "Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIaGLa domain is dispensable for binding to tissue factor but important for activation of factor X," J. Biol. Chem. 269:8007-8013, 1994.
O'Brien et al., "Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model," J. Clin. Invest. 82(1):206-211, 1988.
Paborsky et al., "Lipid association, but not the transmembrane domain, is required for tissue factor activity," J. Biol. Chem. 266(32):21911-21916, 1991.
Paborsky et al., "Purification of recombinant human tissue factor," Biochemistry 28(20): 8072-8077, 1989.
Rehemtulla et al., "High level expression of recombinant human tissue factor in chinese hamster ovary cells as a human thromboplastin," Thromb. Haemost. 65(5):521-527, 1991.
Ruf and Edgington, "Structural biology of tissue factor, the initiator of thrombogenesis in vivo," FASEB J. 8:385-390, 1994.
Ruf and Edgington, "Two sites in the tissue factor extracellular domain mediate the recognition of the ligand factor VIIa," Proc. Natl. Acad. Sci. USA. 88:8430-8434, 1991.
Ruf et al., "Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function," J. Biol. Chem. 266:2158-2166, 1991.
Ruf et al., "Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII," J. Biol. Chem. 267(31):22206-22210, 1992.
Ruf et al., "Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex," J. Biol. Chem. 267(9):6375-6381, 1992.
Sakai and Kisiel, "Formation of tissue factor activity following incubation of recombinant human tissue factor apoprotein with plasma lipoproteins," Thromb. Res. 60(3):213-222, 1990.
ten Cate et al., "The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor," J. Clin. Invest. 92:1207-1212, 1993.
Warr et al., "Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity," Blood 75(7):1481-1489, 1990.
Weiss et al., "Evidence for the presence of tissue factor activity on subendothelium," Blood 73(4):968-975, 1989.
Zacharski et al., "Tumor cell procoagulant and urokinase expression in carcinoma of the ovary," J. Natl. Cancer Inst. 85(15):1225-1230, 1993.
U.S. Application No. 08/273,567, filed Jul. 11, 1994; (Attorney Docket No. UTSD:419). (file history).
Co-Pending U.S. Application No. 08/482,369, filed Jun. 7, 1995; (Attorney Docket No. UTSD:433). (file history).
Co-Pending U.S. Application No. 08/485,482, filed Jun. 7, 1995; (Attorney Docket No. UTSD:456). (file history).
Co-Pending U.S. Application No. 08/487,427, filed Jun. 7, 1995; (Attorney Docket No. UTSD:457). (file history) U.S. Pat 60074555.
Co-Pending U.S. Application No. 08/479,733, filed Jun. 7, 1995; (Attorney Docket No. UTSD:459). (file history).
Co-Pending U.S. Application No. 08/472,631, filed Jun. 7, 1995; (Attorney Docket No. UTSD:460). (file history).
Co-Pending U.S. Application No. 08/479,727, filed Jun. 7, 1995; (Attorney Docket No. UTSD:461 and UTSD:462).
Gao Boning
King Steven W.
Thorpe Philip E.
Bansal Geetha P.
Board of Regents , The University of Texas System
LandOfFree
Combined tissue factor and chemotherapeutic methods and composit does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined tissue factor and chemotherapeutic methods and composit, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined tissue factor and chemotherapeutic methods and composit will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-465811